产品
编 号：F743679
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 1262787-83-6
产品详情
生物活性：
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors.
体内研究：
Patritumab (1 mg/mouse; i.p.; twice a week for 4 weeks) combines with 1 mg Cetuximab and restores Cetuximab sensitivity in DiFi-HRG tumor xenografts model in mice.Heregulin produced by colorectal cancer tumors harboring wild-type KRAS induces Cetuximab resistance, and that combination therapy with cetuximab and patritumab overcomes such resistance in vivo.Animal Model:Female athymic nude mice (BALB/c; 5-6 weeks old) with DiFi-Mock1 or DiFi-HRG4 (s.c.)
Dosage:1 mg/body
Administration:Intraperitoneal injection; twice a week for 4 weeks
Result:Individual Patritumab treatment had little effect on the growth of tumors formed by either cell line.Combination of Cetuximab and Patritumab induced substantial regression of DiFi-HRG4 xenografts.
体外研究：
Patritumab targets to the extracellular domain (ECD) of HER3 and (10 μg/mL; 5 d) induces DiFi-HRG4 cells apoptosis.Patritumab (10 μg/mL; 6 h) markedly inhibits the phosphorylation of HER3 and AKT, without affecting that of ERK, in DiFi-HRG4 cells.Patritumab (10 μg/mL; 48 h) also induces the cleavage of PARP accompanied with both up-regulation of BIM and down-regulation of survivin expression.
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors.
体内研究：
Patritumab (1 mg/mouse; i.p.; twice a week for 4 weeks) combines with 1 mg Cetuximab and restores Cetuximab sensitivity in DiFi-HRG tumor xenografts model in mice.Heregulin produced by colorectal cancer tumors harboring wild-type KRAS induces Cetuximab resistance, and that combination therapy with cetuximab and patritumab overcomes such resistance in vivo.Animal Model:Female athymic nude mice (BALB/c; 5-6 weeks old) with DiFi-Mock1 or DiFi-HRG4 (s.c.)
Dosage:1 mg/body
Administration:Intraperitoneal injection; twice a week for 4 weeks
Result:Individual Patritumab treatment had little effect on the growth of tumors formed by either cell line.Combination of Cetuximab and Patritumab induced substantial regression of DiFi-HRG4 xenografts.
体外研究：
Patritumab targets to the extracellular domain (ECD) of HER3 and (10 μg/mL; 5 d) induces DiFi-HRG4 cells apoptosis.Patritumab (10 μg/mL; 6 h) markedly inhibits the phosphorylation of HER3 and AKT, without affecting that of ERK, in DiFi-HRG4 cells.Patritumab (10 μg/mL; 48 h) also induces the cleavage of PARP accompanied with both up-regulation of BIM and down-regulation of survivin expression.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备